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Introduction
Coronary artery disease (CAD) is still a major 
health problem throughout the world. This disease 
causes a decrease in the quality of life of sufferers and 
is the most common cause of death from heart disease. 
Until now, based on the Global Burden of Disease 
Study, an estimated 7.2 million people worldwide die 
every year due to CHD [1].
Endothelial progenitor cell (EPC) has a role in 
the process of atherosclerosis at each stage where this 
process is the pathogenesis of CAD. A decrease in the 
number and function of EPC begins when various kinds 
of classic risk factors for atherosclerosis appear. This 
reduced amount and function of EPC will aggravate 
existing conditions of endothelial dysfunction, inhibit the 
collateral formation, and fail to compensate for severe 
stenosis. This is probably the cause of high rates of 
major cardiovascular events in patients with low EPC 
numbers and functions regardless of the severity 
of CAD [2]. EPC also plays an important role in the 
angioplasty process. Patients with intracoronary stents 
need a rapid reendothelialization process to prevent the 
occurrence of in-stent thrombosis and the development 
of neointima. This is proven by the occurrence of 
restenosis in patients with low EPC levels [3].
Various trials have been conducted to increase 
the number and function of EPC. Garlic is a natural 
component that is currently believed to prevent and treat 
cardiovascular disease. Garlic works as an antioxidant 
that increases the production of nitric oxide (NO) and 
hydrogen sulfide (H2S) which can cause vasodilation 
and improve endothelial function [4]. Garlic also has the 
ability to inhibit the activity of angiotensin-converting 
enzymes so that it can reduce blood pressure [5]. The 
organosulfur component contained in garlic is also able 
to prevent oxidation of low-density lipoprotein which is 
responsible for the process of atherosclerosis, which 
can reduce the number and function of EPC. In some 
literature, it is said that garlic can inhibit abnormal cell 
growth that has the potential for malignancy. However, 
in cells which have properties as precursors, it is said 
that garlic can increase the number of these cells either 
through increased proliferation or through inhibition 
of apoptosis. However, it is still unknown whether the 
nature of the trigger for apoptosis or cell proliferation 
from garlic is related to the size of the dose or not, 
hence the need for further investigation [6]. Therefore, 
we conducted this study to prove the beneficial effect of 
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Abstract
BACKGROUND: The reduced number and function of endothelial progenitor cell (EPC) in stable coronary 
artery disease (SCAD) patients aggravate endothelial dysfunction and inhibit neovascularization, thus lead to 
atherosclerosis. Garlic is currently believed to increase the number and function of EPC. 
AIM: Therefore, this in vitro study was conducted to analyze the effect of garlic extract (allicin) on the proliferation of 
EPC in patients with SCAD. 
METHODS: Mononuclear cells were isolated from peripheral blood of eight SCAD patients and cultured on colony-
forming unit (CFU)-Hill medium for 3 days. Samples were divided into two groups: Group treated with allicin and 
control group. The treatment group was then divided into three subgroups which received 10, 50, and 100 mg/
ml of doses and incubated for 48 h. EPC proliferation was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) cell proliferation assay. Immunohistochemical method of CD34+ was performed 
for EPC identification. Data were analyzed using independent t-test and ANOVA. 
RESULTS: MTT assay showed a significant increase in EPC proliferation in the allicin group compared to the control 
group (0.2811 ± 0.008 vs. 0.194 ± 0.151, p < 0.05) and significant improvements were observed in each dose 
increment. CFU-Hill quantification shows the addition of EPC colony in high-dose allicin. Immunohistochemical 
method shows positive CD34+ expression. 
CONCLUSION: Allicin increases EPC proliferation dose-dependently from peripheral blood of SCAD patients. 
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garlic which can improve neovascularization process in 
ischemic tissue through its influence on the number and 
function of EPC.
Methods
This study was an in vitro exploratory laboratory 
experimental study using EPCs from the peripheral 
blood of eight patients with stable CAD (SCAD) using 
a “posttest-only control group design.” This laboratory 
research was conducted at the stem cell laboratory, 
Institute of Tropical Disease, Airlangga University 
for 4 months period (January 2017–April 2017). The 
sample was peripheral blood EPC isolated from eight 
stable SCAD patients taken by purposive sampling. The 
inclusion criteria of the subjects were male who showed 
stable symptoms of angina pectoris, aged 40–59 years, 
and had stenotic lesions ≥50% left main coronary arteries 
and ≥70% in one or more other major coronary arteries 
based on angiography. Subjects with a history of stenting, 
acute myocardial infarction, diabetes mellitus, smoking, 
critical limb ischemia, CABG history, and anemia were 
excluded from the criteria of the study subjects.
Subjects were grouped into a control group 
which did not get treatment and the group given allicin, 
which was divided into three subgroups and received 
10, 50, and 100 mg/ml of doses each. Mononuclear 
cells were isolated from peripheral blood using Ficoll 
Histopaque and then cultured in the media for 3 days. 
The treatment was given on the 4th day in the form of 
adding allicin. Observations of cell responses were 
carried out 2 days after treatment. The examination 
includes immunofluorescence using CD34, assessment 
of EPC proliferation using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) proliferation assay, 
and quantification of the number of colonies formed. The 
data obtained were analyzed using the SPSS 20 with 
inferential statistical analysis and ANOVA statistical tests.
Results
Patients’ characteristics
The subjects of this study were eight 
blood samples, whose basic characteristics are 
shown in Table 1. The average age of subjects was 
54.5 ± 4.31 years, with the youngest age of 48 years 
and the oldest age of 59 years. Cardiovascular risk 
factors obtained in the study subjects were dyslipidemia 
and hypertension, where all subjects received 
antihypertensive drugs and anti-lipid statins.
Comparison of EPC proliferation between 
the allicin and control groups
EPC proliferation was calculated using the 
MTT method and the cell absorbance results in optical 
density. Then, the data normality test was carried out 
from the effects of EPC proliferation calculations in all 
treatment and control groups using the Kolmogorov–
Smirnov statistical test with the results of all data 
distributed normally. The data were then analyzed to 
determine the differences between the allicin group 
with a dose of 50 μg/ml (X2) and the control group (C) 
using the two samples t-test.
EPC proliferation in the group that received 
allicin was higher than the control group, which was 
0.2811 ± 0.008 compared to 0.194 ± 0.151. This 
result shows an increase in EPC proliferation with the 
administration of allicin. Statistical data analysis using 
the two-sample independent t-test was used to observe 
differences in the two groups. There was a significant 
difference in the EPC proliferation between the allicin 
groups and control groups (p = 0.000).
Differences in EPC proliferation in allicin 
with low, medium, and high doses
The differences in EPC proliferation between 
the groups given low-dose allicin (X1), medium (X2), 
and high (X3) extract, as shown in Figure 1.
Table 1: Demographic and baseline patient characteristics
Variable Mean ± SD
Age (years) 54.5 ± 4.31
Systolic blood pressure (mmHg) 137.5 ± 24.35
Diastolic blood pressure (mmHg) 80 ± 7.56
Heart rate (beat/min) 86 ± 8.68
Body mass index (kg/m2) 25.39 ± 2.13
Total cholesterol (mg/dL) 200.5 ± 74.75
LDL (mg/dL) 145 ± 61.11
Triglycerides (mg/dL) 97 ± 11.64
HDL (mg/dL) 35 ± 7.64
Ejection fraction left ventricle (%) 53.5 ± 4.11
LDL: Low-density lipoprotein, HDL: High-density lipoprotein, SD: Standard deviation.
Figure 1: Differences in EPC proliferation in the allicin extract of 
various doses
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Based on data analysis, there was a difference 
in EPC proliferation between the groups given low, 
medium, and high allicin. Statistical tests were performed 
using ANOVA for EPC proliferation data between the 
groups and then followed by a significance test using 
the least significant difference (LSD) test. Obtained 
EPC proliferation results increased significantly when 
were given allicin a dose of 50 μg/ml compared with 
a dose of 10 μg/ml (p = 0.005). EPC proliferation also 
had significant increase by administering allicin dose 
of 100 μg/ml compared to 50 μg/ml (p = 0.000). The 
proliferation difference between allicin dose of 100 μg/ml 
was also significant compared to allicin extract with a 
dose of 10 μg/ml (p = 0.000).
Based on data analysis, there was a difference 
in EPC proliferation between the groups given low, 
medium, and high allicin. Statistical tests were 
performed using ANOVA for EPC proliferation data 
between the groups and then followed by a significance 
test using the LSD test. Obtained EPC proliferation 
results increased significantly by giving allicin a 
dose of 50 μg/ml compared with a dose of 10 μg/ml 
(p = 0.005). EPC proliferation also had significant 
increase by administering allicin dose of 100 μg/ml 
compared to 50 μg/ml (p = 0.000). The proliferation 
difference between allicin dose of 100 μg/ml was also 
significant compared to allicin extract with a dose of 
10 μg/ml (p = 0.000).
Examination of colony-forming unit (CFU) 
in the allicin and control groups
Observation and calculation of CFU were done 
to observe and assess the function of the living EPC. 
After proliferating, EPC tends to form colonies which will 
later differentiate into endothelial cells. Observations 
were made in the low-dose, high-dose, and control group 
of allicin on the 6th day. Figures 2-5 show microscopic 
images of the control group CFU and allicin.
The number of colonies formed in the control 
group, the low, medium, and high allicin was different, 
as listed in Table 2. 
Table 2: Number of colony‑forming unit in the control group 
and allicin group
Group CFU 10 μg/ml CFU 100 μg/ml
Control 9
Allicin 7 14
CFU: Colony-forming unit.
The number of colonies formed in the low-dose 
garlic extract group was lower than the control group, 
but at high doses, the number of colonies is higher than 
the control group.
Figure 3: Colony-forming unit microscopic picture of allicin dose of 
10 μg/ml
Figure 4: Colony-forming unit microscopic picture of allicin dose of 
100 μg/ml
Figure 5: Microscopic picture of EPC colonies at colony-forming unitFigure 2: Microscopic picture of the control group colony-forming unit
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Immunofluorescence examination
One positive marker for EPC is CD34. This 
CD34 marker will be expressed on young EPCs that 
are more mature. The examination was carried out on 
one of the wells used to grow CFU. After calculating the 
colony, the preparation was washed using PBS solution 
and prepared for immunofluorescence examination 
using CD34. From observations using fluorescence 
microscopy, CD34 expressions were obtained, which 
were indicated by the presence of EPC cells that had 
green fluorescent colors such as Figure 6.
NO bioavailability through the PI3K/Akt pathway so that 
it will inhibit the EPC apoptosis pathway and increase 
the amount [8], [9].
In allicin, there are various genes and are 
categorized based on their biological processes. 
The upregulated gene in allicin will produce a cellular 
response in the form of increased synthesis of adhesion 
molecules, increased expression of anti-apoptosis, and 
repair of damaged cell surface receptors. However, if 
a cell has the potential to proliferate without control, 
then the downregulation gene in allicin will inhibit the 
cell’s signal transduction. Upregulated genes in allicin 
include glutamate-cysteine ligase modifier (GCLM); 
HO-1; thioredoxin reductase 1 and 2; SLC7A11 (xCT); 
and DUSP1 (MKP1). Allicin can easily penetrate and 
enter through the cell membrane from EPC by diffusion 
toward the intracellular and conjugate with the thiol group 
from glutathione (GSH) to form global surgery student 
alliance (GSSA). The formation of GSSA together with 
the GCLM gene will increase intracellular GSH levels 
to 8-15-fold [10], [11]. Increased GSH levels will also 
increase telomerase activity, so cell proliferation will also 
increase. Aging and apoptosis in EPC which leads to 
rapid progression of atherothrombosis occur when GSH 
levels are low due to the inactivation of telomerase [12]. 
The results of this study reinforce the notion that allicin 
can directly influence EPC proliferation in vitro.
The previous research from Oommen et al. 
and Li et al. explained that allicin ability to increase 
EPC proliferation turned out to be in line with increasing 
dose, concentration, and time. EPC proliferation will be 
optimal by giving allicin a dose of 40–50 µg/ml, but at 
doses above 50 µg/ml, it will cause condensation from 
the cell nucleus and form apoptotic bodies which are 
characteristic of apoptosis [8], [13]. In this study, we 
had similar results, in which low, moderate, and high 
doses can increase EPC proliferation.
EPC has the ability to migrate to form a colony. 
Colony counts describe the cumulative characteristics 
of EPC quantities and functions including differentiation, 
proliferation, aging, and migration activities [14]. 
Interestingly in this study, there were fewer colonization 
results compared to controls in low-dose allicin, but the 
number of colonies increased in the administration of 
high-dose allicin. Until now, there have been no studies 
explaining the effects of giving allicin to the formation 
of EPC colonies. It is known that the EPC migration 
process to approach each other and form colonies is 
influenced by many factors. Various kinds of mediators 
such as eNOS and NO and chemokine-chemokine 
which are chemoactive such as SDF-1, lipid mediators 
(sphingosine-1 phosphate), and MCP-1 or interleukin 
can increase EPC migration [14], [15]. Because allicin 
works in a dose, concentration, and time-dependent 
manner, it is possible that at high doses, it can increase 
the ability of EPC migration through increasing VEGF 
expression. However, the CFU examination in this study 
was only done once as a confirmation that cultured 
Figure 6: Immunofluorescence in CD34 expression
Discussion
In this study, analyses indicated that there 
was a significant difference in EPC proliferation with 
the administration of allicin, shown by an increase in 
proliferation in the treatment group compared to the 
control group. These results were in accordance with 
the previous studies by Zhang and Guo who reported 
that the administration of allicin could increase EPC 
proliferation activities through regulation of vascular 
endothelial growth factor (VEGF) and stromal cell-
derived factor (SDF)-1 expression [7]. Another in vitro 
studies from Li et al. also showed the same results, 
which found an increase in proliferation of cells by 
administering allicin at doses of 10–40 μg/ml, but at 
higher doses, proliferation activity decreased. It is said 
that this increase in proliferation is caused by allicin 
being able to accelerate the cell cycle toward the 
S phase or synthesis phase [8].
The organosulfur component contained in 
allicin can activate the Akt and extracellular-regulated 
kinase (ERK) signal transduction pathways 1/2. Allicin 
will increase the expression and activity of cyclin D1 so 
that it will accelerate EPC to enter the S cycle of the cell 
and increase EPC proliferation. The increase in Akt can 
activate mammalian target of rapamycin receptors found 
on EPC to increase its proliferation. In vivo, allicin can 
activate endothelial NO synthase (eNOS) and increase 
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EPCs can grow well without directly assessing whether 
EPC has a good function for differentiation.
Increased EPC proliferation with allicin 
administration has been proven in this study. The 
effects of allicin both directly and indirectly through 
the mechanism of cytokine activation can increase 
the amount and proliferation of EPC. It is allicin effect 
on EPC proliferation that might explain the effects of 
improvement in cardiovascular disease.
This research still has many limitations. 
The mechanism of the influence of allicin on EPC 
proliferation was not examined in this study. This study 
only proves the existence of a direct effect of allicin on 
the proliferation of EPC regardless of all processes of 
balance in the body. Further research on the mechanism 
of EPC proliferation through the ERK 1/2, Akt, and GSH 
and telomerase activities still needs to be done. This 
research is still carried out in vitro. To confirm the effect 
of allicin in patients with SCAD, it still requires research 
in vivo. The slight difference in results with the previous 
studies also needs to be confirmed by further research 
with bigger sample sizes. In addition, further research is 
needed regarding the dose of lethal allicin so that it can 
be used to find out at what dosage allicin can increase 
proliferation or even pro-apoptosis.
Conclusion
Administration of allicin is proven to increase EPC 
proliferation in peripheral blood of SCAD patients. There 
is a significant difference in EPC proliferation in patients 
with SCAD where the increase in EPC proliferation is in 
line with increasing doses that show the dose-dependent 
effect of allicin. However, further research is needed 
using a larger number of samples to confirm the effect 
of allicin administration on proliferation and apoptosis of 
EPC. Further research on signal transduction pathways 
which causes EPC proliferation is also needed.
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